This week’s biotechnology news headlines include, Congress working on $1.1 billion to fight Zika, scientists find form of CRISPR with new capabilities, job growth in in US biotech industry, Novartis opens $1 billion research center in China, FDA asks companies to select 10 suffixes for biosimilar names, and Kite Pharma and Cell Design Labs partner on CAR T-Cell immunotherapies.
Cell Culture Events
Cell Line Development & Engineering – June 13-15, 2016 – Parc 55 Wyndham San Francisco, CA
Progress in Continuous Biomanufacturing – June 27-28, 2016 – Robinson College, Cambridge, UK
The conference is enhanced by the participation of several leading industrial technologists, scientific, vendors and also leading academics from Europe and USA. They have come forward to share their experience and knowledge to provide a better understanding of the current technologies and their application in continuous biomanufacturing. There is also a plenary lecture by a distinguished professor in the field of bioprocessing, and you will also benefit from access to unpublished data. This meeting will address several advancements and their successful application with data in the Technology both Upstream and downstream and also on Initiatives to process developments and project to the future direction of the industry. By joining with us you can benefit from the current state of-the-art advancements in continuous manufacturing and also learn about the successful organisations that are developing and applying these methods in-house.
Viral Safety and Raw Materials – June 2016, Vienna, Austria
“Just a few years ago, Crispr was a cipher — something that sounded to most ears like a device for keeping lettuce fresh. Today, Crispr-Cas9 is widely known as a powerful way to edit genes. Scientists are deploying it in promising experiments, and a number of companies are already using it to develop drugs to treat conditions ranging from cancer to sickle-cell anemia.”
If you like this story, please see our blog titled “The CRISPR/Cas9 System and its Applications”
“The U.S. bioscience industry grew to nearly 1.66 million jobs in 2014—up 2.2% from 2012, and nearly 10% since 2001, according to a report released today at the 2016 Biotechnology Innovation Organization (BIO) International Convention.”
If you like this story, please see our blog titled “Gene Therapy Strengthened by Recent Successes”
“The US Food and Drug Administration (FDA) on Wednesday announced a new tweak to its guidance on the non-proprietary names for biosimilars and will allow companies to propose 10 suffixes for each new biosimilar and biologic, as opposed to the previous proposal of having each company select one random suffix.”
If you like this story, please see our blog titled “Cool Tool – Off the Shelf Optimized CHO Media and Feed”